Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 1999

View Archived Issues

Dusa updates Levulan PDT development

Endorex study shows immune response stimulation by ImmTher in human cancer cells

Immune Response reports data from phase I colon cancer vaccine study

Medco third quarter progress marked by initiation of phase II coronary diagnostic trial

Trega Biosciences and Novartis expand R&D collaboration

Antiviral advisory committee meets in early November to discuss NDA for anti-HIV drug

Alpha-glucosidase inhibition as a target for development of broad-based anti-hepatitis virus agents

Eisai allowed to market Alzheimer's drug in Japan

Ariad discloses a wide series of cellular signal transduction inhibitors

EPO receptor ligands unrelated to primary EPO structure patented by Chugai

Immunogenic compositions for the treatment or prevention of HPV infections from Cantab

Wyeth-Ayerst reports U.S. launch of immunosuppressant

Preclinical results indicate a new target for RP therapy: calcium channel blockade

American Cyanamid claims nonpeptide MMP/TACE inhibitors for wide range of indications

New treatments for schizophrenia in the pipeline at Merck

Inflazyme to commence phase Ib studies with new oral asthma therapy

RotaShield withdrawn from the market following reports of intussusception

Preclinical review of AR-R15896AR presented at recent symposium

Progress toward a universal flu vaccine?

Dopascan as a potential biomarker for Parkinson's disease; clinical results presented

KRP-297: a novel thiazolidinedione that improves impaired fatty acid oxidation

New treatment for GERD now available in U.S.

Neurocrine Biosciences' NBI-3001 granted fast track designation

Dura and Spiros initiate pivotal clinical program for Beclomethasone Spiros

Highlights from EASD annual meeting: DPP-IV inhibitor shows promise in type II diabetes

Lotronex NDA up for review next month by GI advisory committee

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...